[{"id":"f8d87fba-1ad4-4662-baab-e93772837874","acronym":"Agni-01","url":"https://clinicaltrials.gov/study/NCT06060613","created_at":"2023-09-29T19:11:12.291Z","updated_at":"2025-02-25T14:03:51.690Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","source_id_and_acronym":"NCT06060613 - Agni-01","lead_sponsor":"Obsidian Therapeutics, Inc.","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • OBX-115"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2025-02-19"},{"id":"f54e7e6b-bb69-4a1c-88ad-1174200e27c6","acronym":"IOV-EAP 402","url":"https://clinicaltrials.gov/study/NCT05398640","created_at":"2022-06-01T16:00:15.608Z","updated_at":"2025-02-25T14:17:00.566Z","phase":"","brief_title":"Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release","source_id_and_acronym":"NCT05398640 - IOV-EAP 402","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Amtagvi (lifileucel)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-17"},{"id":"f514461c-de65-4d4b-ac81-de9f774794d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04625205","created_at":"2021-01-19T20:35:22.976Z","updated_at":"2025-02-25T16:26:10.622Z","phase":"Phase 1","brief_title":"A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma","source_id_and_acronym":"NCT04625205","lead_sponsor":"BioNTech US Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT221"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-12-19"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"26912b3a-874b-41d0-8280-5bf68e728ed7","acronym":"IOV-CLL-01","url":"https://clinicaltrials.gov/study/NCT04155710","created_at":"2021-01-18T20:16:34.491Z","updated_at":"2024-07-02T16:35:04.463Z","phase":"Phase 1/2","brief_title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","source_id_and_acronym":"NCT04155710 - IOV-CLL-01","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" TP53 • IL2","pipe":" | ","alterations":" TP53 mutation • TP53 mutation + Chr del(17p)","tags":["TP53 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IOV-2001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-10"},{"id":"89ba88cd-80a1-431f-9a1a-3255d4d165a7","acronym":"NCI-2021-11063","url":"https://clinicaltrials.gov/study/NCT05176470","created_at":"2022-01-04T13:53:34.324Z","updated_at":"2024-07-02T16:35:15.802Z","phase":"Phase 1","brief_title":"Neoadj Admin Autologous Tumor Infiltrating Lymphocytes \u0026 Pembrolizumab for Treatment of Adv Melanoma Patients","source_id_and_acronym":"NCT05176470 - NCI-2021-11063","lead_sponsor":"Richard Wu","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-07"},{"id":"ee98277b-261b-44a8-a033-c2fa8d278537","acronym":"THETIS","url":"https://clinicaltrials.gov/study/NCT03997474","created_at":"2021-07-29T18:53:19.522Z","updated_at":"2024-07-02T16:35:24.579Z","phase":"Phase 1/2","brief_title":"ATL001 in Patients With Metastatic or Recurrent Melanoma","source_id_and_acronym":"NCT03997474 - THETIS","lead_sponsor":"Achilles Therapeutics UK Limited","biomarkers":" PD-L1 • BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ATL 001"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-01-04"},{"id":"cfe7d0e3-d8e7-4ac0-b5ec-34f2283813e9","acronym":"C-144-01","url":"https://clinicaltrials.gov/study/NCT02360579","created_at":"2021-01-18T11:14:09.234Z","updated_at":"2024-07-02T16:35:43.303Z","phase":"Phase 2","brief_title":"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02360579 - C-144-01","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Amtagvi (lifileucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-07-12"},{"id":"89fea682-b243-4d0a-b33b-68ffee2754d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05144698","created_at":"2021-12-03T17:53:38.066Z","updated_at":"2024-07-02T16:35:51.936Z","phase":"Phase 1/2","brief_title":"RAPA-201 Therapy of Solid Tumors","source_id_and_acronym":"NCT05144698","lead_sponsor":"Rapa Therapeutics LLC","biomarkers":" EGFR • ALK • BRCA","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation","tags":["EGFR • ALK • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-03-30"},{"id":"1551fdea-4388-4abb-8e4a-606aa2a8d9a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03970382","created_at":"2021-01-18T19:31:43.454Z","updated_at":"2024-07-02T16:36:05.198Z","phase":"Phase 1a/1b","brief_title":"A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors","source_id_and_acronym":"NCT03970382","lead_sponsor":"PACT Pharma, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Proleukin (aldesleukin) • NeoTCR-P1"],"overall_status":"Suspended","enrollment":" Enrollment 21","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 08/12/2022","primary_completion_date":" 08/12/2022","study_txt":" Completion: 08/12/2022","study_completion_date":" 08/12/2022","last_update_posted":"2022-08-18"},{"id":"5b7ed973-4ac5-4c9d-8a94-360ea8f63cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05106946","created_at":"2021-11-04T16:57:12.845Z","updated_at":"2024-07-02T16:36:20.869Z","phase":"Phase 1","brief_title":"Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma","source_id_and_acronym":"NCT05106946","lead_sponsor":"Fundamenta Therapeutics, Ltd.","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ThisCART22"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 10/25/2023","primary_completion_date":" 10/25/2023","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2021-11-11"},{"id":"a6865147-d492-4b7c-ab7e-c32c506cfa4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02500550","created_at":"2022-01-21T22:01:20.459Z","updated_at":"2024-07-02T16:36:30.087Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor","source_id_and_acronym":"NCT02500550","lead_sponsor":"Kiadis Pharma","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rhitol (allodepleted T-cell immunotherapeutics) • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/09/2015","start_date":" 10/09/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 12/17/2018","study_completion_date":" 12/17/2018","last_update_posted":"2021-05-18"},{"id":"371d58a2-25f1-4a65-ae93-d66ba3aa87c2","acronym":"DEPLETHINK","url":"https://clinicaltrials.gov/study/NCT03466320","created_at":"2021-01-18T17:05:05.194Z","updated_at":"2024-07-02T16:36:30.744Z","phase":"Phase 1/2","brief_title":"DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2","source_id_and_acronym":"NCT03466320 - DEPLETHINK","lead_sponsor":"Celyad Oncology SA","biomarkers":" TP53 • NKG2D","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CYAD-01 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-05-04"},{"id":"8ca8a02d-8743-4c6b-a40b-ee548609ffbc","acronym":"OVSTAR","url":"https://clinicaltrials.gov/study/NCT04389229","created_at":"2021-01-18T21:11:12.940Z","updated_at":"2024-07-02T16:36:37.358Z","phase":"Phase 1/2","brief_title":"OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)","source_id_and_acronym":"NCT04389229 - OVSTAR","lead_sponsor":"Immetacyte Ltd","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CoTIL-01 • UTIL-01 • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2020-12-15"},{"id":"eba3f2d8-df2f-4db2-8b50-7d1ebd4b5a6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04368182","created_at":"2021-06-30T14:53:52.902Z","updated_at":"2024-07-02T16:36:45.519Z","phase":"Phase 1","brief_title":"AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT04368182","lead_sponsor":"Zhejiang University","biomarkers":" HLA-A • AFP","pipe":" | ","alterations":" HLA-A*02 • AFP expression","tags":["HLA-A • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-TCR055"],"overall_status":"Unknown status","enrollment":" Enrollment 3","initiation":"Initiation: 04/13/2020","start_date":" 04/13/2020","primary_txt":" Primary completion: 08/31/2020","primary_completion_date":" 08/31/2020","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2020-04-29"},{"id":"182788c6-1780-477a-87bc-0e5bf73a6189","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971747","created_at":"2021-06-30T14:53:40.918Z","updated_at":"2024-07-02T16:36:46.431Z","phase":"Phase 1","brief_title":"AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT03971747","lead_sponsor":"Cellular Biomedicine Group Ltd.","biomarkers":" HLA-A • AFP","pipe":" | ","alterations":" HLA-A*02 • AFP expression","tags":["HLA-A • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-TCR055"],"overall_status":"Unknown status","enrollment":" Enrollment 9","initiation":"Initiation: 08/06/2019","start_date":" 08/06/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2020-04-07"},{"id":"deedd814-45d7-45c3-b510-5266ccf71ee4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03196414","created_at":"2021-01-18T15:45:41.018Z","updated_at":"2024-07-02T16:36:59.951Z","phase":"Phase 1/2","brief_title":"Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03196414","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" SDC1","pipe":" | ","alterations":" SDC1 positive","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SDC1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CART-138 • CART-138/BCMA/19/more"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2019-05-02"}]